Carnegie Mellon University Invests $34,000 in Predictive Oncology Inc. (NASDAQ:POAI)

Carnegie Mellon University acquired a new stake in shares of Predictive Oncology Inc. (NASDAQ:POAI) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,358 shares of the medical instruments supplier’s stock, valued at approximately $34,000. Predictive Oncology comprises approximately 0.0% of Carnegie Mellon University’s holdings, making the stock its 5th biggest holding. Carnegie Mellon University owned about 0.26% of Predictive Oncology as of its most recent SEC filing.

Separately, Raymond James & Associates acquired a new position in shares of Predictive Oncology in the 3rd quarter valued at about $378,000. Hedge funds and other institutional investors own 9.04% of the company’s stock.

Predictive Oncology Stock Performance

NASDAQ POAI traded up $0.32 during mid-day trading on Thursday, reaching $1.66. 246,542 shares of the stock were exchanged, compared to its average volume of 29,666. The business’s 50 day moving average is $2.48 and its 200-day moving average is $2.92. Predictive Oncology Inc. has a 1 year low of $1.12 and a 1 year high of $7.12. The company has a market capitalization of $6.74 million, a P/E ratio of -0.48 and a beta of 1.28.

Predictive Oncology (NASDAQ:POAI) last posted its quarterly earnings data on Thursday, March 28th. The medical instruments supplier reported ($0.85) earnings per share for the quarter. The company had revenue of $0.34 million for the quarter. Predictive Oncology had a negative return on equity of 104.21% and a negative net margin of 785.62%.

Predictive Oncology Profile

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.